SCHEMBL1764089

SCHEMBL1764089

CS(=O)(=O)c1ccc(C(=O)N2CC=C(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 7/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.38
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
EPHX2 P34913 1/20 0.36
WDR5 P61964 1/20 0.36
NAMPT P43490 2/20 0.35
RXFP1 Q9HBX9 1/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA7 P43166 2/20 0.34
CA9 Q16790 2/20 0.34
CA14 Q9ULX7 2/20 0.34
JAK1 P23458 1/20 0.34
SCN9A Q15858 1/20 0.34
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12593566 0.89 NAMPT (0.38) SLC9A1CYP3A4MMP2MMP3NAMPT
SCHEMBL1763592 0.87 SLC9A1 (0.49) SLC9A1CYP3A4MMP2MMP3NAMPT
SCHEMBL1763602 0.83 P2RX7 (0.39) SLC9A1CYP3A4MMP2MMP3LMNA
SCHEMBL1763741 0.81 SLC9A1 (0.49) SLC9A1CYP2C9NAMPTJAK1
SCHEMBL1763452 0.80 JAK1 (0.36) SLC9A1CYP3A4WDR5JAK1
SCHEMBL1764093 0.79 CYP2C9 (0.48) SLC9A1CYP3A4CYP2C9MMP2MMP3
SCHEMBL1764203 0.78 SLC9A1 (0.71) SLC9A1CYP3A4CYP2C9
SCHEMBL29802958 0.71 TRPV1 (0.47)
SCHEMBL1763649 0.71 SLC9A1 (0.61) SLC9A1CYP3A4CYP2C9
SCHEMBL1763622 0.71 SLC9A1 (0.73) SLC9A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-19 US disclosed
WO-2010005783-A1 PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118262-A1 Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors NHERF1, SLC9A1, SLC9A5 SLC9A1 2/4885CYP3A4 3075/4885CYP2C9 1660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.